Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells $47,050.00 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Steven Pieper sold 5,000 shares of Xeris Biopharma stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $9.41, for a total transaction of $47,050.00. Following the completion of the transaction, the insider directly owned 1,351,053 shares of the company’s stock, valued at approximately $12,713,408.73. This trade represents a 0.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Pieper also recently made the following trade(s):

• On Tuesday, September 1st, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.50, for a total transaction of $42,500.00.
• On Wednesday, August 12th, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.50, for a total transaction of $42,500.00.
• On Tuesday, July 7th, Steven Pieper sold 27,600 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.52, for a total value of $235,152.00.
• On Monday, July 6th, Steven Pieper sold 17,400 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.50, for a total value of $147,900.00.

Xeris Biopharma Price Performance

Shares of NASDAQ XERS opened at $9.08 on Monday. The business’s 50 day moving average price is $8.46 and its two-hundred day moving average price is $7.32. The company has a market cap of $1.66 billion, a PE ratio of -82.55 and a beta of 0.53. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 17.00. Xeris Biopharma Holdings, Inc. has a twelve month low of $5.25 and a twelve month high of $11.33.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. The business had revenue of $92.10 million during the quarter, compared to analyst estimates of $90.12 million. On average, analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current year.

Institutional Trading of Xeris Biopharma

Hedge funds have recently added to or reduced their stakes in the company. Integrated Wealth Concepts LLC bought a new stake in Xeris Biopharma in the 2nd quarter valued at $74,000. Allworth Financial LP raised its stake in Xeris Biopharma by 86.4% in the 2nd quarter. Allworth Financial LP now owns 4,315 shares of the company’s stock worth $34,000 after purchasing an additional 2,000 shares in the last quarter. Allianz Asset Management GmbH acquired a new stake in Xeris Biopharma in the 2nd quarter worth about $314,000. Corient Private Wealth LP bought a new stake in Xeris Biopharma in the 2nd quarter valued at about $1,458,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Xeris Biopharma in the 2nd quarter valued at about $89,000. 42.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on XERS. Leerink Partners raised their price target on Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a report on Thursday, September 10th. Weiss Ratings lowered shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Wall Street Zen upgraded shares of Xeris Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Finally, Barclays lifted their target price on shares of Xeris Biopharma from $9.00 to $12.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Xeris Biopharma currently has an average rating of “Hold” and an average price target of $12.80.

Xeris Biopharma Company Profile

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology, and related rare or chronic conditions. The company uses proprietary formulation technologies designed to deliver medicines that are difficult to formulate or administer through conventional methods, including its XeriSol and XeriJect platforms.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection used to treat severe hypoglycemia; Keveyis (dichlorphenamide), a treatment for primary periodic paralysis; and Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with Cushing’s syndrome.